03759.HK
Pharmaron Beijing Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 29.00
−2.03%Year over year
Reported trailing growth
- Revenue
- +15.0%
- EBITDA
- +23.6%
- EBIT
- +23.7%
- EPS
- +21.5%
- Free cash flow
- +265.9%
- Operating cash flow
- +33.2%
Forward estimates
Based on analyst estimates
- Revenue
- +15.5%
- EBITDA
- +100.5%
- EPS
- +55.6%
Three-year CAGR
- Revenue
- +11.1%
- EBITDA
- +9.1%
- EBIT
- +4.5%
- Net income
- +6.6%
- EPS
- +1.5%
- Free cash flow
- +3.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026